Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults
Status:
Not yet recruiting
Trial end date:
2022-08-05
Target enrollment:
Participant gender:
Summary
Gates MRI-RSM01-101 is a Phase 1, randomized, double-blind, placebo-controlled,
dose-escalation study to evaluate the safety and tolerability, pharmacokinetics, occurrence
of ADA, and assessment of neutralizing antibody against RSV after administration of single
intravenous or intramuscular doses of RSM01 to healthy adults.